# A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

> **NCT00967018** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 77 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT00967018
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2013-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00967018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00967018, "A Long Term Safety Study of Degarelix in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00967018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*